FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313880048> ?p ?o ?g. }

• W4313880048 endingPage "363" @default.
• W4313880048 startingPage "354" @default.
• W4313880048 abstract "Active surveillance is a safe and effective strategy for men with lower-risk prostate cancer who want to avoid local therapy; however, many patients on active surveillance progress to active treatment (eg, prostatectomy or radiation). We hypothesized that apalutamide would decrease active surveillance attrition rates through downstaging low-grade tumors.This was an open-label, single-arm, phase II study testing 90 days of oral apalutamide 240 mg daily in men with low- to intermediate-risk prostate cancer on active surveillance. The primary objective was to determine the percentage of patients with a negative biopsy immediately following treatment. Secondary objectives were to assess long-term clinical outcomes, quality of life, safety, and biomarkers of response/resistance.Twenty-three patients enrolled and 22 completed 90 days of apalutamide with post-treatment biopsy. Fifteen (65%) had Grade Group 1 disease, and all others had Grade Group 2 disease. Seven (30%) had favorable- to intermediate-risk disease. Of 22 evaluable patients, 13 (59%) had no residual cancer on post-treatment biopsy. The median time to first positive biopsy was 364 days (95% CI: 91-742 days). The impact of apalutamide on quality of life was minimal and transient. Decipher risk classifier revealed a greater number of negative post-treatment biopsies in those with higher baseline genomic risk score (P = .01).The negative repeat biopsy rate following 90 days of apalutamide was high in men with prostate cancer followed on active surveillance. Apalutamide was safe, well tolerated, and had minimal impact on quality of life. Randomized studies evaluating the effects of apalutamide in men enrolled on active surveillance are warranted." @default.
• W4313880048 created "2023-01-10" @default.
• W4313880048 creator A5014339741 @default.
• W4313880048 creator A5014582211 @default.
• W4313880048 creator A5018941587 @default.
• W4313880048 creator A5023363049 @default.
• W4313880048 creator A5024005013 @default.
• W4313880048 creator A5027535552 @default.
• W4313880048 creator A5034997866 @default.
• W4313880048 creator A5044591528 @default.
• W4313880048 creator A5046716593 @default.
• W4313880048 creator A5050405997 @default.
• W4313880048 creator A5052152752 @default.
• W4313880048 creator A5054590690 @default.
• W4313880048 creator A5067800417 @default.
• W4313880048 creator A5071006955 @default.
• W4313880048 creator A5080866168 @default.
• W4313880048 creator A5087520734 @default.
• W4313880048 date "2023-02-01" @default.
• W4313880048 modified "2023-09-30" @default.
• W4313880048 title "Pathological Effects of Apalutamide in Lower-risk Prostate Cancer: Results From a Phase II Clinical Trial" @default.
• W4313880048 cites W1154461499 @default.
• W4313880048 cites W1966818523 @default.
• W4313880048 cites W1983145936 @default.
• W4313880048 cites W1984301572 @default.
• W4313880048 cites W1998343146 @default.
• W4313880048 cites W2000056288 @default.
• W4313880048 cites W2021480933 @default.
• W4313880048 cites W2029087193 @default.
• W4313880048 cites W2096544053 @default.
• W4313880048 cites W2102558162 @default.
• W4313880048 cites W2106869018 @default.
• W4313880048 cites W2110881680 @default.
• W4313880048 cites W2130032754 @default.
• W4313880048 cites W2131357804 @default.
• W4313880048 cites W2140203312 @default.
• W4313880048 cites W2149339272 @default.
• W4313880048 cites W2167331614 @default.
• W4313880048 cites W2287642617 @default.
• W4313880048 cites W2772104639 @default.
• W4313880048 cites W2792086148 @default.
• W4313880048 cites W2804681057 @default.
• W4313880048 cites W2898746949 @default.
• W4313880048 cites W2911777256 @default.
• W4313880048 cites W2947014957 @default.
• W4313880048 cites W2999081098 @default.
• W4313880048 cites W2999472739 @default.
• W4313880048 cites W3009200944 @default.
• W4313880048 cites W3113153998 @default.
• W4313880048 cites W4282968863 @default.
• W4313880048 cites W4287877836 @default.
• W4313880048 cites W4291675870 @default.
• W4313880048 doi "https://doi.org/10.1097/ju.0000000000003038" @default.
• W4313880048 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36621991" @default.
• W4313880048 hasPublicationYear "2023" @default.
• W4313880048 type Work @default.
• W4313880048 citedByCount "0" @default.
• W4313880048 crossrefType "journal-article" @default.
• W4313880048 hasAuthorship W4313880048A5014339741 @default.
• W4313880048 hasAuthorship W4313880048A5014582211 @default.
• W4313880048 hasAuthorship W4313880048A5018941587 @default.
• W4313880048 hasAuthorship W4313880048A5023363049 @default.
• W4313880048 hasAuthorship W4313880048A5024005013 @default.
• W4313880048 hasAuthorship W4313880048A5027535552 @default.
• W4313880048 hasAuthorship W4313880048A5034997866 @default.
• W4313880048 hasAuthorship W4313880048A5044591528 @default.
• W4313880048 hasAuthorship W4313880048A5046716593 @default.
• W4313880048 hasAuthorship W4313880048A5050405997 @default.
• W4313880048 hasAuthorship W4313880048A5052152752 @default.
• W4313880048 hasAuthorship W4313880048A5054590690 @default.
• W4313880048 hasAuthorship W4313880048A5067800417 @default.
• W4313880048 hasAuthorship W4313880048A5071006955 @default.
• W4313880048 hasAuthorship W4313880048A5080866168 @default.
• W4313880048 hasAuthorship W4313880048A5087520734 @default.
• W4313880048 hasConcept C121608353 @default.
• W4313880048 hasConcept C126322002 @default.
• W4313880048 hasConcept C126894567 @default.
• W4313880048 hasConcept C141071460 @default.
• W4313880048 hasConcept C143998085 @default.
• W4313880048 hasConcept C168563851 @default.
• W4313880048 hasConcept C2775934546 @default.
• W4313880048 hasConcept C2779466945 @default.
• W4313880048 hasConcept C2780192828 @default.
• W4313880048 hasConcept C2781217009 @default.
• W4313880048 hasConcept C71924100 @default.
• W4313880048 hasConceptScore W4313880048C121608353 @default.
• W4313880048 hasConceptScore W4313880048C126322002 @default.
• W4313880048 hasConceptScore W4313880048C126894567 @default.
• W4313880048 hasConceptScore W4313880048C141071460 @default.
• W4313880048 hasConceptScore W4313880048C143998085 @default.
• W4313880048 hasConceptScore W4313880048C168563851 @default.
• W4313880048 hasConceptScore W4313880048C2775934546 @default.
• W4313880048 hasConceptScore W4313880048C2779466945 @default.
• W4313880048 hasConceptScore W4313880048C2780192828 @default.
• W4313880048 hasConceptScore W4313880048C2781217009 @default.
• W4313880048 hasConceptScore W4313880048C71924100 @default.
• W4313880048 hasIssue "2" @default.
• W4313880048 hasLocation W43138800481 @default.

• next